At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
Psilocybin (Usona Institute) +1 moredrug
Likely dose
Psilocybin (Usona Institute) 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout
In Brief
A Phase 3 clinical trial evaluating Psilocybin (Usona Institute) and Active placebo for Burnout, Caregiver and 5 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This study aims to investigate the effects of a single dose of psilocybin, delivered in the contextof pre- and post-dose psychotherapy, on symptoms of depression and burnout suffered by healthcare clinicians as a result of frontline work in the COVID pandemic.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBurnout, Caregiver, Burnout, Professional, COVID-19, Depression, Post Traumatic Stress Disorder, Moral Injury
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartMar 2022
Primary CompletionDec 2023
Study CompletionJun 2024
TodayJul 2026
First PostedDec 20, 2021
Enrollment StartMar 3, 2022
Primary CompletionDec 30, 2023
Study CompletionJun 30, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.5 years ago
Interventions
Psilocybin (Usona Institute)drug
PAP + psilocybin 25 mg
Active placebodrug
PAP + niacin 250mg